Skip to main content
. 2023 Jul 12;14:1213285. doi: 10.3389/fimmu.2023.1213285

Figure 5.

Figure 5

(A) Schema of tumor study. (B) Tumor growth curve of C3.43 tumor bearing mice vaccinated with four weekly doses of 10 µg HPV vaccine mRNA or Luciferase control mRNA. N=10 mice per group. Data presented as mean ± SEM. CR: complete responders. (C) Survival rates of C3.43 tumor bearing mice vaccinated with four weekly doses of 10 μg HPV vaccine mRNA or Luciferase control mRNA. N=10 mice per group. Data presented as Kaplan-Meier curves. (D) Tumor growth curve of C3.43 challenged (10 control/never vaccinated mice) and C3.43 rechallenged (the 6 mice who received the vaccine and completely responded by day 60) animals. Data presented as mean ± SEM. CR: complete responders. (E) ELISpot analysis of IFNγ positive Spot forming units (SFU) in splenocytes derived from C3.43 tumor bearing- control mice (10 animals, never vaccinated, collected on Day91), -vaccinated and CR mice after rechallenge (6 animals, collected on Day91),and stimulated ex vivo with either a vehicle control, 5 μg/mL HPV16 E7 peptides, 5 μg/mL HPV16 E6 peptides or T-activator CD3/CD28 control. Data presented as mean ± SEM. Differences between groups were tested using two-way ANOVA test (***, P<0.001).